{"entity":{"id":"nct04632108","kind":"trial","name":"A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of ASKB589 Injection in advanced solid tumours, run by Jiangsu Aosaikang Pharmaceutical Co., Ltd., active and no longer recruiting.","summary":"A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT04632108 by Jiangsu Aosaikang Pharmaceutical Co., Ltd., with 199 participants enrolled, started 2021-01-28 and due to reach its primary completion in 2025-10-31. Interventions recorded: ASKB589 Injection.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04632108","url":"https://clinicaltrials.gov/study/NCT04632108"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04632108","phase":"1/2","setting":"A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors","sponsor":"Jiangsu Aosaikang Pharmaceutical Co., Ltd.","enrolled":199,"outcomes":[]},"route":"/trials/nct04632108/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}]}}